Illumina Stock (ILMN) Jumps after Insiders Invest $1.5 Million

Illumina (ILMN) shares are up in today’s trading after executives disclosed buying roughly $1.5 million worth of the healthcare company’s stock. Indeed, CEO Jacob Thaysen made two significant purchases: 5,850 shares at $80.84 per share and 6,500 shares at $80.88, for a total of nearly $1 million. These transactions bring his total ownership to 83,390 shares. It is worth noting that insider buying from a CEO is often seen as a positive indicator because it suggests that leadership believes the stock is undervalued or that business fundamentals are improving.

Separately, Chief Financial Officer Ankur Dhingra also purchased 6,100 shares at $81.21 each, for a total of $495,381. His holdings now stand at approximately 24,906 shares. Like a CEO, when a CFO, who is responsible for the company’s financial health, buys shares, it typically adds confidence to the company’s financial outlook. Interestingly, these purchases come at a time when Illumina has faced increased investor scrutiny and market volatility, so the timing could imply that leadership sees a turning point or recovery ahead.

Insider buying often attracts investor attention because executives have the best view of their company’s prospects. Unlike public investors, they have firsthand knowledge of upcoming projects, earnings trends, and operational momentum. When both the CEO and CFO make sizable investments in the company at the same time, it’s seen as a strong vote of confidence and can serve as a bullish signal to the broader market.

Is ILMN a Good Stock to Buy?

Turning to Wall Street, analysts have a Moderate Buy consensus rating on ILMN stock based on nine Buys, nine Holds, and two Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average ILMN price target of $111.47 per share implies 38.6% upside potential.

See more ILMN analyst ratings